drugset
drugset / Trial / NCT06147856

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

NCT06147856 ↗

Phase 1/2 Withdrawn ModernaTX, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The main goal of this study is to assess the safety, and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU).

Timeline

Start
2024-03-29
Primary completion
2026-08-10
Completion
2027-08-05

Outcome

Outcome not reported

Stopped (Enrollment): “The Sponsor no longer intends to recruit to this study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-3210 Unknown — Intravenous

Indications

phenylketonuria